morrocan.png
_MG_7369-2.png
iStock_74518153_MEDIUM.jpg
morrocan.png

SEngine Precision Medicine


The Search Engine For Identifying Personalized Cancer Treatments

SCROLL DOWN

SEngine Precision Medicine


The Search Engine For Identifying Personalized Cancer Treatments

SEngine Precision Medicine has engineered an innovative approach to identify and develop the next generation of cancer targeted drugs.  Built on its Founders’ work of more than 25 years at the Fred Hutchinson Cancer Research Center, SEngine employs functional genomics and robotic testing of drugs in live patient organoids to match newly developed drugs to individual cancer patients. SEngine strives to fulfill the promise of personalized medicine providing cancer patients with effective, targeted, and less-toxic treatments.

_MG_7369-2.png

Using a Unique Platform to Identify Drug Targets


Using a Unique Platform to Identify Drug Targets


A major revolution is occurring in cancer treatments wherein broadly prescribed chemotherapies are being replaced by personalized therapies. But progress is slow. To date, only 20 or so of the more than 20,000 genes in the human genome have been developed as targets for FDA-approved drugs. There remain, then, thousands of potential genes (i.e. gene protein products) to develop as future drug targets.  SEngine’s approach offers a tremendous opportunity to broaden the arsenal of targeted and effective treatments.

The results of SEngine’s functional screening assay—which is performed on a wide variety of tumor types— have matriculated into an extensive and rich dataset which facilitates a novel method of target discovery within a previously untargeted area of the human genome. 

SEngine Precision Medicine has already identified, validated, and patented novel therapeutic targets that DNA sequencing alone cannot reveal.

SEngine’s strategy for discovering novel drug targets integrates the concept of “synthetic lethality” to tackle “undruggable” oncogenes and loss of tumor suppressor function.

iStock_74518153_MEDIUM.jpg

and Deliver Personal Oncology


and Deliver Personal Oncology


Our scientists recognize that no two cancers are the same. 

SEngine’s approach is ready to meet the increasing demand for “personalized cancer medicine.”  Despite the expansion of genetic profiling, there remains a large percentage of patients for whom no biomarkers of drug efficacy are detected or who become refractory to their targeted therapy or chemotherapy regimen. SEngine responds to these challenges by incorporating functional precision medicine to identify potentially lifesaving therapeutic options.


Current clients include individual patients, pharmaceuticals and cancer research institutions seeking to find solutions for unmet needs in precision oncology. Our laboratory is now CLIA certified in order to integrate personalized functional drug screens into the standard-of-care diagnostic workup of future cancer patients.

To learn more about how SEngine is helping to transform drug development and cancer treatments,